Diabetes Awareness Week: Advancing Diabetic Therapies using Euglycaemic Clamp Studies

Diabetes Week, observed annually during the third week of June, serves as a crucial platform to raise awareness about diabetes and encourage conversations surrounding this prevalent disease. Navitas Life Sciences stands as a strategic partner to support small,medium and large pharmas in rapidly bringing effective anti-diabetic therapies to the market. With our state-of-the-art euglycemic clamp studies and comprehensive study capabilities, we offer tailored solutions to accelerate drug development and address unique needs.

According to a recent study, it is estimated that over 100 million people in India have diabetes, and an additional 130+ million individuals are at a higher risk of developing the disease, representing a significant increase of over 40% from the previous figure of 70 million just four years ago. 4.3 million people in the UK are estimated to be living with Diabetes, while the Centers for Disease Control and Prevention (CDC) states that more than 37 million people in the US have diabetes. It is important, therefore, to find suitable therapy that will aid in better management and control of diabetes.

Navitas Life Sciences: Your Strategic Partner in Diabetes Research and Euglycemic Clamp Studies

At Navitas Life Sciences, we possess extensive experience in conducting euglycemic clamp studies, the gold standard for assessing insulin sensitivity in humans. Our capabilities enable us to measure the glucose-lowering effect of biosimilar insulin compounds using a variable glucose infusion rate (GIR). With a focus on precision and safety, our experts ensure constant monitoring of subjects throughout the study, employing advanced instrumentation such as glucose analyzers, ECLIA analyzers, and highly sensitive triple quad mass spectrophotometers.

We utilize validated methods to estimate insulin, analogs, and metabolites, employing analytical platforms like ligand binding assays and chromatographic assays for accurate analysis at picogram levels. Rigorous data analysis further enhances our ability to derive meaningful insights.

Leveraging Our Study Experience

Navitas Life Sciences possesses in-depth domain expertise, allowing us to identify challenges and provide effective solutions . With our extensive study experience, we have successfully conducted research on various insulin compounds, including Regular Insulin Human, Isophane Suspension, Insulin Glargine Injection, insulin Aspart, Biphasic Isophane Insulin Injection, and Soluble Insulin Injection. This breadth of expertise allows us to cater to the unique needs of different compounds and develop tailored strategies to meet your specific objectives.

Sciex-6500

Elisa Plate reader

Elisa Plate washer

Leading the Way in Biosimilar Insulin Development:

Navitas Life Sciences recognizes the complexities involved in biosimilar insulin development. With our vast experience and technical know-how, we are well-equipped to support your journey and guide you through the intricacies of this field. Our state-of-the-art equipment and methodologies ensure that we can expedite the development process, assisting you in bringing your biosimilar insulin to the market ahead of competitors.

As Diabetes Week highlights the significance of awareness and understanding regarding diabetes, Navitas Life Sciences remains at the forefront of supporting anti-diabetic therapies and biosimilar insulin development. Our expertise in euglycemic clamp studies, comprehensive study capabilities, and commitment to delivering efficient results make us the ideal partner to navigate the challenges of diabetes research. Join forces with Navitas life sciences and accelerate the development of your anti-diabetic therapies.

To learn more about our services and solutions, reach out to us at This email address is being protected from spambots. You need JavaScript enabled to view it.